Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.
Charlie Gourley
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; GlaxoSmithKline; MSD; Roche
Honoraria - Boehringer Ingelheim; Chugai Pharma; MSD; Roche
Research Funding - AstraZeneca; GlaxoSmithKline; Roche
Other Remuneration - Boehringer Ingelheim; MSD; Roche
Andrena McCavigan
Employment or Leadership Position - Almac Diagnostics
Timothy Perren
Honoraria - Roche
Research Funding - Roche
James Paul
No relevant relationships to disclose
Caroline Ogilvie Michie
No relevant relationships to disclose
Michael Churchman
No relevant relationships to disclose
Alistair Williams
No relevant relationships to disclose
W. Glenn McCluggage
No relevant relationships to disclose
Mahesh Parmar
No relevant relationships to disclose
Richard S. Kaplan
No relevant relationships to disclose
Laura A. Hill
Employment or Leadership Position - Almac Diagnostics
Iris A Halfpenny
Employment or Leadership Position - Almac Diagnostics
Eamonn J. O'Brien
Employment or Leadership Position - Almac Diagnostics
Olaide Raji
Employment or Leadership Position - Almac Diagnostics
Steve Deharo
Employment or Leadership Position - Almac Diagnostics
Timothy Davison
Employment or Leadership Position - Almac Diagnostics
Patrick Johnston
Consultant or Advisory Role - Almac Diagnostics
Katherine E. Keating
Employment or Leadership Position - Almac Diagnostics
D. Paul Harkin
Employment or Leadership Position - Almac Diagnostics
Richard D. Kennedy
Employment or Leadership Position - Almac Diagnostics